An Exploratory Cost‐Utility Analysis of Screening and Treating Immigrants in Canada for Hepatitis D
Journal of Viral Hepatitis · 2026-08 · 33 (8)
DOI: 10.1111/jvh.70214 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Viral Hepatitis, online erschienen am 19.07.2026. Verfasst von Jiahao Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, University of Waterloo, Kitchener, Ontario, Canada. Hauptthemen laut MEDLINE: Mass Screening, Antiviral Agents, Emigrants and Immigrants, Hepatitis D. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Hepatitis D is common among immigrants in Canada, who account for approximately 23% of the population and tend to originate from high‐endemic countries. Mortality rates are notably high among those with chronic infections, and immigrants are less likely to engage in screening and treatment services. This paper aims to assess the cost‐utility of screening and treating Hepatitis D Virus (HDV)‐positive immigrants in Canada compared with a scenario in which no screening is conducted. This analysis takes a public‐payer perspective, uses a lifetime time horizon with a 1.5% annual discount rate, and expresses costs in 2023 Canadian dollars. A state‐transition model representing the natural progression of chronic hepatitis B and hepatitis D was developed in TreeAge Pro and mapped onto three interventions: screening and treatment with bulevirtide; screening and treatment with pegylated interferon alfa‐2a; and screening and treatment with both bulevirtide and pegylated interferon alfa‐2a. The analysis was conducted in accordance with the guidelines of Canada's Drug Agency. The incremental cost‐effectiveness ratio (ICER) was estimated for each intervention. Model sensitivity was performed using both univariate and probabilistic sensitivity analyses. All screening and treatment strategies resulted in a reduction in cases of decompensated cirrhosis, hepatocellular carcinoma and liver death, with combination therapy demonstrating the most favourable outcomes. Nevertheless, HDV screening and treatment with pegylated interferon alfa‐2a monotherapy was the only cost‐effective strategy (ICER: $23,177/QALY). While monotherapy with pegylated interferon alfa‐2a proved cost‐effective, combination therapy with bulevirtide is likely more clinically effective and may be cost‐effective if treatment costs decrease significantly.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, University of Waterloo, Kitchener, Ontario, Canada.
- School of Public Health Sciences, University of Waterloo, Waterloo, Ontario, Canada.
ORCID-Profile: Diedron Lewis, John-Michael Gamble, Zahid A Butt
Zitieren
APA
Zhao, J., Lewis, D., Gamble, J. M., Butt, Z. A., & Wong, W. W. L. (2026). An Exploratory Cost‐Utility Analysis of Screening and Treating Immigrants in Canada for Hepatitis D. Journal of Viral Hepatitis, 33(8). https://doi.org/10.1111/jvh.70214
Vancouver
Zhao J, Lewis D, Gamble JM, Butt ZA, Wong WWL. An Exploratory Cost‐Utility Analysis of Screening and Treating Immigrants in Canada for Hepatitis D. Journal of Viral Hepatitis. 2026;33(8). doi:10.1111/jvh.70214
BibTeX
@article{Zhao2026,
author = {Zhao, Jiahao and Lewis, Diedron and Gamble, John-Michael and Butt, Zahid A and Wong, William W L},
title = {An Exploratory Cost‐Utility Analysis of Screening and Treating Immigrants in Canada for Hepatitis D},
journal = {Journal of Viral Hepatitis},
year = {2026},
volume = {33},
number = {8},
doi = {10.1111/jvh.70214}
}
EUVIMED